BD PharmingenTM MitoStatus Red

Description

Analysis of Cells Stained with BD Pharmingen MitoStatus Red Panel 1. Flow cytometric analysis of MitoStatus Red in Jurkat Cells. Jurkat cells were treated with 0.025 % DMSO 4 h, solid line histograms , 5 muM camptothecin 4 h, Left Plot, dashed line histogram or 50 muM FCCP 20 min, Right Plot, dashed line histogram , and then stained with 100 nM BD Pharmingen MitoStatus Red 15 min, Cat. No. 564697 Panel 2. Two-color flow cytometric analysis of MitoStatus Red staining in Jurkat Cells. Jurkat cells were treated with 0.025 % DMSO Left Plot or 5 muM camptothecin Right Plot for 4 h and stained with 100 nM MitoStatus Red 15 min . Cells were resuspended in Annexin V Binding Buffer and stained with FITC Annexin V 15 min, Cat. No. 556419 . Co-staining shows two main populations: healthy cells that are MitoStatus Red-positive and Annexin V-negative, and apoptotic or dead cells that are MitoStatus Red-negative and FITC Annexin V-positive. Compared to the DMSO-vehicle treated control, treatment with camptothecin results in an increase in the MitoStatus Red-negative and FITC Annexin V-positive population, indicating that more cells are undergoing apoptosis. Loss of mitochondrial membrane potential is an earlier apoptotic marker, so a small population of cells in transition is MitoStatus Red-negative, FITC Annexin V-negative. Flow cytometry was performed using a BD LSRFortessa Cell Analyzer System. Panel 3. Immunofluorescent imaging of MitoStatus Red in HeLa Cells. HeLa cells were treated 3 h with 0.02 % DMSO Left Image or 1 muM staurosporine Right Image . Cells were stained 30 min with 200 nM MitoStatus Red and 5 mug/mL Hoechst. Staining media was then removed and replaced with DPBS. Compared to the vehicle-treated control, staurosporine-treated cells show a decrease in mitochondrial staining with MitoStatus Red, and pyknotic nuclei characteristic of apoptotic cells. Cells were imaged on a BD Pathway 435 Cell Analyzer and merged using BD Attovision software. Analysis of Cells Stained with BD Pharmingen MitoStatus Red Panel 1. Flow cytometric analysis of MitoStatus Red in Jurkat Cells. Jurkat cells were treated with 0.025 % DMSO 4 h, solid line histograms , 5 muM camptothecin 4 h, Left Plot, dashed line histogram or 50 muM FCCP 20 min, Right Plot, dashed line histogram , and then stained with 100 nM BD Pharmingen MitoStatus Red 15 min, Cat. No. 564697 Panel 2. Two-color flow cytometric analysis of MitoStatus Red staining in Jurkat Cells. Jurkat cells were treated with 0.025 % DMSO Left Plot or 5 muM camptothecin Right Plot for 4 h and stained with 100 nM MitoStatus Red 15 min . Cells were resuspended in Annexin V Binding Buffer and stained with FITC Annexin V 15 min, Cat. No. 556419 . Co-staining shows two main populations: healthy cells that are MitoStatus Red-positive and Annexin V-negative, and apoptotic or dead cells that are MitoStatus Red-negative and FITC Annexin V-positive. Compared to the DMSO-vehicle treated control, treatment with camptothecin results in an increase in the MitoStatus Red-negative and FITC Annexin V-positive population, indicating that more cells are undergoing apoptosis. Loss of mitochondrial membrane potential is an earlier apoptotic marker, so a small population of cells in transition is MitoStatus Red-negative, FITC Annexin V-negative. Flow cytometry was performed using a BD LSRFortessa Cell Analyzer System. Panel 3. Immunofluorescent imaging of MitoStatus Red in HeLa Cells. HeLa cells were treated 3 h with 0.02 % DMSO Left Image or 1 muM staurosporine Right Image . Cells were stained 30 min with 200 nM MitoStatus Red and 5 mug/mL Hoechst. Staining media was then removed and replaced with DPBS. Compared to the vehicle-treated control, staurosporine-treated cells show a decrease in mitochondrial staining with MitoStatus Red, and pyknotic nuclei characteristic of apoptotic cells. Cells were imaged on a BD Pathway 435 Cell Analyzer and merged using BD Attovision software. Show More Analysis of Cells Stained with BD Pharmingen MitoStatus Red Panel 1. Flow cytometric analysis of MitoStatus Red in Jurkat Cells. Jurkat cells were treated with 0.025 % DMSO 4 h, solid line histograms , 5 muM camptothecin 4 h, Left Plot, dashed line histogram or 50 muM FCCP 20 min, Right Plot, dashed line histogram , and then stained with 100 nM BD Pharmingen MitoStatus Red 15 min, Cat. No. 564697 Panel 2. Two-color flow cytometric analysis of MitoStatus Red staining in Jurkat Cells. Jurkat cells were treated with 0.025 % DMSO Left Plot or 5 muM camptothecin Right Plot for 4 h and stained with 100 nM MitoStatus Red 15 min . Cells were resuspended in Annexin V Binding Buffer and stained with FITC Annexin V 15 min, Cat. No. 556419 . Co-staining shows two main populations: healthy cells that are MitoStatus Red-positive and Annexin V-negative, and apoptotic or dead cells that are MitoStatus Red-negative and FITC Annexin V-positive. Compared to the DMSO-vehicle treated control, treatment with camptothecin results in an increase in the MitoStatus Red-negative and FITC Annexin V-positive population, indicating that more cells are undergoing apoptosis. Loss of mitochondrial membrane potential is an earlier apoptotic marker, so a small population of cells in transition is MitoStatus Red-negative, FITC Annexin V-negative. Flow cytometry was performed using a BD LSRFortessa Cell Analyzer System. Panel 3. Immunofluorescent imaging of MitoStatus Red in HeLa Cells. HeLa cells were treated 3 h with 0.02 % DMSO Left Image or 1 muM staurosporine Right Image . Cells were stained 30 min with 200 nM MitoStatus Red and 5 mug/mL Hoechst. Staining media was then removed and replaced with DPBS. Compared to the vehicle-treated control, staurosporine-treated cells show a decrease in mitochondrial staining with MitoStatus Red, and pyknotic nuclei characteristic of apoptotic cells. Cells were imaged on a BD Pathway 435 Cell Analyzer and merged using BD Attovision software.